文献速递脑血管病

带状疱疹疫苗与抗病毒治疗对缺血性卒中风险的影响

Effect of herpes zoster vaccine and antiviral treatment on risk of ischemic stroke.
PubMed 文献 · Neurology · 2020-07-07

本研究纳入2008至2017年87,405例≥66岁带状疱疹并急性缺血性卒中的Medicare按服务付费受益人,采用自对照病例系列设计分析带状疱疹与卒中的关联。结果显示带状疱疹后0-14天卒中风险显著升高(IRR 1.89),且该风险未受带状疱疹活疫苗或抗病毒治疗影响。

要点

  • 带状疱疹后0-14天急性缺血性卒中风险显著升高(IRR 1.89)。
  • 带状疱疹活疫苗和抗病毒治疗未显著改变带状疱疹相关卒中风险。
  • 建议按推荐接种带状疱疹疫苗以预防带状疱疹及其相关卒中。

核心结论

  • 带状疱疹后急性缺血性卒中风险显著增加,且该风险未受带状疱疹活疫苗和抗病毒治疗影响。
  • 研究结果提示遵循推荐接种带状疱疹疫苗对预防带状疱疹及带状疱疹相关卒中具有重要意义。

研究设计与样本

  • 研究纳入2008至2017年87,405例≥66岁诊断为带状疱疹和急性缺血性卒中的Medicare按服务付费受益人。
  • 采用自对照病例系列设计,比较风险期与控制期的急性缺血性卒中发生率,估计发生率比(IRR)。
  • 受益人按疫苗接种和抗病毒治疗状态分为四组:无疫苗无抗病毒、仅疫苗、仅抗病毒、两者均有,并检验交互作用。

主要发现

  • 带状疱疹后0-14、15-30、31-90和91-180天的IRR分别为1.89(95%CI 1.77-2.02)、1.58(95%CI 1.47-1.69)、1.36(95%CI 1.31-1.42)和1.19(95%CI 1.15-1.23)。
  • 四组受益人占比分别为22.0%、2.0%、70.1%和5.8%(分别对应无疫苗无抗病毒、仅疫苗、仅抗病毒、两者均有)。
  • 疫苗和抗病毒治疗对带状疱疹与急性缺血性卒中关联的效应修饰无统计学证据(交互作用p=0.067)。
  • 带状疱疹与急性缺血性卒中风险的关联模式在年龄组、性别和种族间基本一致。

临床怎么用

  • 临床应关注带状疱疹后近期(尤其0-14天)的急性缺血性卒中风险升高。
  • 不应因患者已接种带状疱疹疫苗或接受抗病毒治疗而忽视带状疱疹后的卒中风险。
  • 建议符合条件者按推荐接种带状疱疹疫苗以预防带状疱疹及其相关卒中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether increased risk of acute ischemic stroke (AIS) following herpes zoster (HZ) might be modified by the status of zoster vaccine live (ZVL) vaccination and antiviral treatment following HZ. METHODS: We included 87,405 Medicare fee-for-service beneficiaries aged ≥66 years diagnosed with HZ and AIS from 2008 to 2017. We used a self-controlled case series design to examine the association between HZ and AIS, and estimated incidence rate ratios (IRRs) by comparing incidence of AIS in risk periods vs control periods. To examine effect modification by ZVL and antiviral treatment, beneficiaries were classified into 4 mutually exclusive groups: (1) no vaccination and no antiviral treatment; (2) vaccination only; (3) antiviral treatment only; and (4) both vaccination and antiviral treatment. We tested for interaction to examine changes in IRRs across 4 groups. RESULTS: Among 87,405 beneficiaries with HZ and AIS, 22.0%, 2.0%, 70.1%, and 5.8% were in groups 1 to 4, respectively. IRRs in 0-14, 15-30, 31-90, and 91-180 days following HZ were 1.89 (95% confidence interval [CI], 1.77-2.02), 1.58 (95% CI, 1.47-1.69), 1.36 (95% CI, 1.31-1.42), and 1.19 (95% CI, 1.15-1.23), respectively. There was no evidence of effect modification by ZVL and antiviral treatment on AIS (p = 0.067 for interaction). The pattern of association between HZ and risk for AIS was largely consistent across age group, sex, and race. CONCLUSIONS: Risk of AIS increased significantly following HZ, and this increased risk was not modified by ZVL and antiviral treatment. Our findings suggest the importance of following recommended HZ vaccination in prevention of HZ and HZ-associated AIS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Yang Q, George MG, Chang A, et al. Effect of herpes zoster vaccine and antiviral treatment on risk of ischemic stroke. Neurology. 2020. PMID: 32636330. doi:10.1212/WNL.0000000000010028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。